We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current EPI market cap is 361.62M. The company's latest EPS is USD -0.6028 and P/E is -2.77.
| Year End September 29 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -11.26M | -23.52M | -37.14M | -36.96M | -32.13M |
| Net Income | -10.44M | -23.45M | -36.81M | -35.1M | -26.58M |
| Year End September 29 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 54.77M | 80.57M | 198.17M | 169.51M | 149.12M |
| Total Liabilities | 5.59M | 1.33M | 4.16M | 2.39M | 3.5M |
| Total Equity | 49.18M | 79.24M | 194.01M | 167.12M | 145.63M |
| Year End September 29 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -12.25M | -16.98M | -25.42M | -28.71M | -19.78M |
| Investing | -46k | -21.74M | -35.02M | -52.35M | -3.53M |
| Financing | 50.81M | 41.78M | 141.99M | 253k | -68k |
| Market Cap | 361.62M |
| Price to Earnings Ratio | -2.77 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 2.19 |
| Price to Book Ratio | 0.51 |
| Dividend Yield | - |
| Shares Outstanding | 44.1M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | 0.00% |
| 52 Week High | 8.20 |
| 52 Week Low | 8.20 |
| Spread (Intraday) | 2.45 (27.37%) |
| Company Name | Essa Pharma Inc |
| Address |
suite 3500, the stack, 1133 melville street vancouver, british columbia V6E 4E5 |
| Website | https://www.essapharma.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
